Literature DB >> 17881144

Long-term improvement in treatment outcome after radiotherapy and hyperthermia in locoregionally advanced cervix cancer: an update of the Dutch Deep Hyperthermia Trial.

Martine Franckena1, Lukas J A Stalpers, Peter C M Koper, Ruud G J Wiggenraad, Wim J Hoogenraad, Jan D P van Dijk, Carla C Wárlám-Rodenhuis, Jan J Jobsen, Gerard C van Rhoon, Jacoba van der Zee.   

Abstract

PURPOSE: The local failure rate in patients with locoregionally advanced cervical cancer is 41-72% after radiotherapy (RT) alone, whereas local control is a prerequisite for cure. The Dutch Deep Hyperthermia Trial showed that combining RT with hyperthermia (HT) improved 3-year local control rates of 41-61%, as we reported earlier. In this study, we evaluate long-term results of the Dutch Deep Hyperthermia Trial after 12 years of follow-up. METHODS AND MATERIALS: From 1990 to 1996, a total of 114 women with locoregionally advanced cervical carcinoma were randomly assigned to RT or RT+HT. The RT was applied to a median total dose of 68 Gy. The HT was given once weekly. The primary end point was local control. Secondary end points were overall survival and late toxicity.
RESULTS: At the 12-year follow-up, local control remained better in the RT+HT group (37% vs. 56%; p=0.01). Survival was persistently better after 12 years: 20% (RT) and 37% (RT+HT; p=0.03). World Health Organization (WHO) performance status was a significant prognostic factor for local control. The WHO performance status, International Federation of Gynaecology and Obstetrics (FIGO) stage, and tumor diameter were significant for survival. The benefit of HT remained significant after correction for these factors. European Organization for Research and Treatment of Cancer Grade 3 or higher radiation-induced late toxicities were similar in both groups.
CONCLUSIONS: For locoregionally advanced cervical cancer, the addition of HT to RT resulted in long-term major improvement in local control and survival without increasing late toxicity. This combined treatment should be considered for patients who are unfit to receive chemotherapy. For other patients, the optimal treatment strategy is the subject of ongoing research.

Entities:  

Mesh:

Year:  2007        PMID: 17881144     DOI: 10.1016/j.ijrobp.2007.07.2348

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

1.  Concerning the final report "Hyperthermia: a systematic review" of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010.

Authors:  R Sauer; H Creeze; M Hulshof; R Issels; O Ott
Journal:  Strahlenther Onkol       Date:  2012-03       Impact factor: 3.621

2.  Hyperthermia and radiation therapy for locally advanced or recurrent breast cancer.

Authors:  Tamer Refaat; Sean Sachdev; Vythialinga Sathiaseelan; Irene Helenowski; Salah Abdelmoneim; Margaret C Pierce; Gayle Woloschak; William Small; Bharat Mittal; Krystyna D Kiel
Journal:  Breast       Date:  2015-04-18       Impact factor: 4.380

3.  Hyperthermia MRI temperature measurement: evaluation of measurement stabilisation strategies for extremity and breast tumours.

Authors:  Cory Wyatt; Brian Soher; Paolo Maccarini; H Cecil Charles; Paul Stauffer; James Macfall
Journal:  Int J Hyperthermia       Date:  2009       Impact factor: 3.914

4.  Should hyperthermia be included in the benefit catalogue for oncologic indications? Commercial interests are presumed behind the editorial of R. Sauer et al.

Authors:  C Wild
Journal:  Strahlenther Onkol       Date:  2013-01       Impact factor: 3.621

Review 5.  Novel agents and treatment techniques to enhance radiotherapeutic outcomes in carcinoma of the uterine cervix.

Authors:  Ajeet Kumar Gandhi
Journal:  Ann Transl Med       Date:  2016-02

6.  Mapping of hyperthermic tumor cell death in a microchannel under unidirectional heating.

Authors:  Fen Wang; Yuhui Li; Lei Chen; Dandan Chen; Xiaolei Wu; Hao Wang
Journal:  Biomicrofluidics       Date:  2012-03-20       Impact factor: 2.800

Review 7.  Heating technology for malignant tumors: a review.

Authors:  H Petra Kok; Erik N K Cressman; Wim Ceelen; Christopher L Brace; Robert Ivkov; Holger Grüll; Gail Ter Haar; Peter Wust; Johannes Crezee
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

8.  Computation of ultimate SAR amplification factors for radiofrequency hyperthermia in non-uniform body models: impact of frequency and tumour location.

Authors:  Bastien Guérin; Jorge F Villena; Athanasios G Polimeridis; Elfar Adalsteinsson; Luca Daniel; Jacob K White; Bruce R Rosen; Lawrence L Wald
Journal:  Int J Hyperthermia       Date:  2017-05-11       Impact factor: 3.914

9.  Small cell carcinoma of vulva: curative multimodal treatment in face of resistance to initial standard chemotherapy.

Authors:  Franziska Eckert; Tanja Fehm; Michael Bamberg; Arndt-Christian Müller
Journal:  Strahlenther Onkol       Date:  2010-08-30       Impact factor: 3.621

Review 10.  Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters.

Authors:  S Triantopoulou; E Efstathopoulos; K Platoni; N Uzunoglou; N Kelekis; V Kouloulias
Journal:  Clin Transl Oncol       Date:  2012-11-21       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.